Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNLI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDenali and Biogen announce Phase 2b Parkinson's trial results for BIIB122
Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
high
Denali and partner Biogen disclosed topline results from the Phase 2b LUMA study testing BIIB122 (DNL151) in early-stage Parkinson's disease patients. This represents a key clinical milestone for the company's neurodegenerative disease pipeline.
Item 8.01 view on EDGAR → -
high
The 8-K filing itself does not include efficacy data or trial outcomes—only that topline results were announced via press release on May 21, 2026. Investors should review the full press release for actual clinical data.
Item 8.01 view on EDGAR → -
medium
Press release dated May 21, 2026 attached as Exhibit 99.1 contains the detailed study results and company commentary on the LUMA trial outcomes.
Exhibit 99.1 view on EDGAR →
Summary
Denali Therapeutics and its partner Biogen announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151) as a treatment for early-stage Parkinson's disease. This is a significant clinical milestone for Denali's neurodegenerative disease franchise, as Phase 2b data typically determines whether a drug candidate advances to pivotal Phase 3 trials. The 8-K filing serves as a formal notification but does not include the actual efficacy or safety data from the trial.
Retail investors should immediately review the attached press release (Exhibit 99.1) and any investor presentation materials to understand whether BIIB122 met its primary endpoints and what the data means for commercial viability. Parkinson's disease represents a large unmet medical need, and positive results could materially impact Denali's valuation and partnership economics with Biogen. Watch for follow-on disclosures about regulatory strategy, additional trial data presentations at medical conferences, and any updates to the Biogen collaboration terms based on these results.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 21, 2026, Denali Therapeutics Inc. (the “Company”) and Biogen Inc. issued a press release announcing topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson’s disease.
Denali and partner Biogen disclosed topline results from their Phase 2b clinical trial (LUMA study) testing BIIB122 (DNL151) as a treatment for early-stage Parkinson's disease. The 8-K does not provide the actual results or efficacy data, only that topline results were announced via press release. This is a material clinical milestone for the company's Parkinson's disease program.
Event · Item 9.01 — Financial Statements and Exhibits
Denali Therapeutics filed an 8-K attaching a press release dated May 21, 2026; no material business event disclosed in the filing body.
Added in current filing · view on EDGAR →
99.1 Press Release dated May 21, 2026
The 8-K attaches a press release dated May 21, 2026 as Exhibit 99.1. The filing body provides no detail about the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify